The jury in a new York trial has found that Teva Pharmaceuticals played a role in fuelling the opioid crisis in the US, and should be held liable for damages, which will be decided later. The decision came after eight days of deliberation by the jurors, and almost six months of legal jousting between the
Month: December 2021
A new technique takes bioprinting — in which an ink of cells is printed, layer by layer, to form a structure — to a whole new, and icy level. Investigators from the Zhang lab at Brigham and Women’s Hospital have developed a technology that they term “cryobioprinting,” a method that uses a bioink embedded with
Development of a systematic evolution platform We began by developing a 96-well plate-based method, wherein 500-µl cultures of evolving M13 bacteriophage (Fig. 1a) are serially diluted with fresh host bacteria twice per hour using an automated liquid handler (Fig. 1b). To enable the pipetting speeds required to approximate continuous flow, we developed a robotic Python
Welcome to this week’s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Kyle LaHucik, and we will feature it here at the end of each week. CRISPR Therapeutics quietly reports R&D chief’s firing in SEC filing CRISPR Therapeutics Tony Ho, M.D., has
Ahead of its New Year’s Day decision deadline at the FDA, Xeris Biopharma has snagged an approval for Recorlev, a drug formerly known as levoketoconazole. Based on results from phase 3 studies called Sonics and Logics, the FDA approved the drug for adults with Cushing’s syndrome. Xeris picked up Recorlev earlier this year in its
As vaccine effectiveness wanes over time, it is generally estimated using a standard Cox or Poisson model that assumes constant vaccine effectiveness over time. However, this is less precise over short time periods, and it indicates the effectiveness of vaccines fairly slowly. Researchers from the University of North Carolina, University of Washington, and the US
Johnson & Johnson’s much-touted crop of bispecific antibodies for cancer generated its first commercial product in May, and the drugmaker has now filed for FDA approval of a second candidate. The latest to reach the regulatory stage is teclistamab, one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J’s Janssen division stemming
A team led by Prof. HU Linhua at the Hefei Institutes of Physical Science of the Chinese Academy of Sciences (CAS) has recently developed a type of self-healing perovskite solar cell by functional combination of polyvinylpyrrolidone (PVP). Related results were published in Journal of Energy Chemistry. A team led by Prof. HU Linhua at the Hefei Institutes of Physical
Ionis’ heart disease drug has had many names over the years, and, now, it has yet another plus a Big Pharma partner in AstraZeneca and billions in potential biobucks possible down the line. The two companies have closed a development and commercialization deal for $200 million upfront, $485 million in additional conditional payments and, last
Russian researchers have developed a strategy to create a cheap and rapid COVID-19 test based on isothermal amplification. According to their publication in Applied Biochemistry and Microbiology, use of this strategy will make it possible to create universal test systems for any of the COVID-19 variants. There are several options for systems that detect traces
Samsung Group is in talks to buy Biogen in a deal that could be worth $42 billion, the Korea Economic Daily reported Wednesday, citing investment banking sources. If the report is true—and if negotiations succeed—Samsung would take control of Biogen at a time when the biotech is laboring to launch its controversial Alzheimer’s drug, Aduhelm,
In a recent study published on the medRxiv* preprint server, researchers carried out an analytical susceptibility test with cultured severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant in seven antigen-detecting rapid diagnostic (Ag-RDTs). Study: Analytical sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for Omicron variant. Image Credit: Roman Zaeits / Shutterstock.com Background Related Stories
Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma’s rival antibody tralokinumab. IL-13 inhibitor tralokinumab has been cleared by the US regulator as Adbry as a treatment for moderate-to-severe atopic dermatitis in adults who can’t control symptoms using topical prescription therapies. The
A novel analysis of medical records for a racially diverse group of more than 6,000 women has added to evidence that some combination of biological, social and cultural factors — and not race alone — is likely responsible for higher rates of preeclampsia among Black women born in the United States compared with Black women
Clinical benefits of combining H&E and IHC on the same slide include conservation of small specimens, such as biopsies, to maximize the amount of clinical information obtained from the specimen, and the ability to evaluate protein expression within the full H&E context, bringing to bear the trove of information that H&E based staining provides the
Sanofi is betting $1 billion on a preclinical pipeline of anti-cancer T-cell engagers. The upfront outlay, plus up to $225 million in milestones, is set to give Sanofi ownership of West Coast immuno-oncology player Amunix Pharmaceuticals. Amunix is building a pipeline of T-cell engagers on XPAT, a technology designed to improve the safety of the
An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate. By identifying the targets of these “broadly neutralizing” antibodies on the spike protein, it might be possible to design vaccines and antibody treatments
Getting patients to stick to medical routines or change their lifestyle for the better isn’t always easy, but don’t worry: There’s an app for that. With so many health issues stemming from lifestyle-related illnesses, it’s no surprise that one of the biggest aspects of the modern lifestyle may be part of the cure. Sidekick Health
A new preprint* research paper under consideration at Nature Portfolio Journal assesses the susceptibility of the Omicron variant to neutralizing antibody response after booster immunization. Whereas the variant completely escapes the neutralizing activity from doubly vaccinated individuals, convalescent individuals, and different monoclonal antibodies in clinical use, the researchers from Germany showed that a booster vaccine
People infected with the Omicron variant of COVID-19 are 50% to 70% less likely to be admitted to hospital than those infected with other variants, according to a UK study. The new analysis from the UK Health Security Agency (UKHSA) also says Omicron infections are estimated to be between 31% to 45% less likely to
- 1
- 2
- 3
- …
- 13
- Next Page »